Ian Kerridge

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Implementing a One Health approach to emerging infectious disease: reflections on the socio-political, ethical and legal dimensions

Chris Degeling, Jane Johnson, Ian Kerridge et al. · BMC Public Health · 2015 · 199 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +12

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy

Biju George, Nalini Pati, Nicole Gilroy et al. · Transplant Infectious Disease · 2010 · 176 citations

Medicine, Hematology, Immunology +17

Evidence, Ethics, and Values: A Framework for Health Promotion

Stacy M. Carter, Lucie Rychetnik, Beverley Lloyd et al. · American Journal of Public Health · 2011 · 136 citations · Full text

Public Health, Health Behavior, Health Promotion +11

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Simon He, Samantha J. Busfield, Mark Hertzberg et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 124 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16